Dawnrays Pharmaceutical (Holdings) Limited Overview
Dawnrays is a vertically integrated, mid-sized Chinese generic pharmaceutical manufacturer controlled by a Hong Kong-incorporated holding structure and run from Suzhou. Its revenue is overwhelmingly domestic (99.7% in 1H2026) and dominated by finished drugs (93.1% of 1H2026 revenue), principally chronic-disease "system specific" medicines — the "An" amlodipine-based anti-hypertensive franchise, Fujian Dawnrays' statins and metformin, the Ruifuen entecavir anti-hepatitis-B tablet and the Xikewei/Xikexin antihistamines — supplemented by cephalosporin injectables and an upstream cephalosporin intermediates/API business that historically underpinned the Group's cost advantage. Since 2018, national volume-based procurement (VBP) has transformed the economics: volumes rose but prices fell, and two expensive plant relocations/new builds (Suzhou Shanfeng Road and Lanzhou) are still running well below capacity. The result is a highly cash-rich (≈RMB1.6bn cash and structured deposits), debt-free company trading below 0.4x book value, with a 25–50% payout policy and a stated pivot toward first-to-market generics, improved new drugs and external pipeline sourcing.
Company's own description
In its filings the Group describes itself as being principally engaged in developing, manufacturing and selling non-patented pharmaceutical medicines, spanning intermediate pharmaceuticals, bulk medicines (APIs) and finished drugs (1H26 IR, note 1.1). It reports two segments: (a) finished drugs, comprising antibiotic and non-antibiotic finished drugs; and (b) intermediates and bulk medicines (1H26 IR, note 2). Management characterises the Group's competitive basis as integration across R&D, production and sales, governance and sound financial management, anchored by a "Quality First, Integrity as Foundation" philosophy (FY24 AR-Ann, Outlook).
Independent characterisation
Dawnrays is best understood as three businesses with very different economics:
-
Branded chronic-disease generics (the profit engine). "System specific medicines" accounted for 88.5% of finished-drug sales in 1H2026 (1H26 IR). The core franchises are anti-hypertensives (the "An" series built around amlodipine besylate tablets "Anneizhen"), lipid-lowering drugs (atorvastatin "Shumaitong", rosuvastatin, plus metformin SR "Yousuheng" from Fujian Dawnrays), antiviral entecavir dispersible tablets "Ruifuen", and antihistamines "Xikewei"/"Xikexin". These products carry high gross margins but are progressively exposed to national and alliance VBP rounds and to "price governance" campaigns that compress listing prices across channels.
-
Cephalosporin injectables (cyclical, VBP-driven). Powder-for-injection products such as "Xianshu" (cefoperazone/sulbactam 1:1), "Xianlian" (2:1) and "Xianding" (cefotaxime) generated rapid growth in 2024–1H2025 after VBP wins, then fell 44.0% in 1H2026 as the continuation of VBP batches 1–8 reset prices (1H26 IR).
-
Intermediates and APIs (loss-making, capacity in ramp-up). Historically the Group's origin (cephalosporin APIs such as cefoperazone sodium and ceftriaxone sodium; 2003 bulk sales were RMB210m, per the 2003 Annual Report), this segment now mainly supplies the Group's own formulation plants (intersegment sales RMB39.6m vs. external RMB37.6m in 1H2026). It lost RMB39.7m at the segment level in 1H2026 because the new Shanfeng Road plant in Suzhou and the Lanzhou base are under-utilised (1H26 IR).
Business and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue model | ~100% product sales, recognised at a point in time; immaterial pilot-test services (RMB2.0m in FY2024); no subscription or licensing revenue | FY24 AR-Ann note 4; 1H26 IR note 3 |
| Product vs. service mix | Product 99.8% / service 0.2% (FY2024); product 100% (1H2026) | FY24 AR-Ann; 1H26 IR |
| Value-chain position | Integrated from intermediates → API → finished dosage (cephalosporins); finished dosage only for most chronic-disease drugs (APIs partially in-house, e.g., new trelagliptin API at Lanzhou) | 1H26 IR; FY24 AR-Ann |
| Customer types | Pharmaceutical distributors (main), hospitals via VBP tenders, pharmacy chains, primary-care/"third-terminal" outlets (village clinics, private institutions), e-commerce platforms; API customers (domestic formulators, overseas buyers) | FY24 AR-Ann; 1H26 IR (Prospect) |
| Customer concentration | Top five customers ≈12% of sales; top five suppliers ≈27% of purchases (FY2025) | FY25 AR summary |
| Credit terms | Generally three months for major customers; advance payment for new customers | 1H26 IR note 10 |
| End-markets | Cardiovascular (hypertension, hyperlipidaemia), metabolic (diabetes), infectious disease (HBV, bacterial infections), allergy, pain/inflammation, psychiatry (trazodone, newly approved), API export | Filings |
Strategy
Stated strategic themes (paraphrased from FY2024 Chairman's Statement and 1H2026 Prospect)
FY2024 Outlook (four priorities, FY24 AR-Ann):
-
Increase R&D investment — focus on chronic diseases, antivirals and anti-infectives; diversify into anti-ageing, nutrition and health; develop generics and innovative drugs with proprietary IP for domestic substitution.
-
Enhance production efficiency — smart manufacturing, lean production and technological innovation to raise capacity utilisation.
-
Expand market channels — deeper terminal coverage, e-commerce and international markets.
-
Sustainable development — environmental infrastructure; carbon peak by 2030 and neutrality by 2060.
1H2026 Prospect (1H26 IR) refines this into:
-
Financial prudence, concentrating on products with clinical value, quality advantages and reasonable returns.
-
R&D: stronger project initiation assessment, milestone management and commercialisation hand-off; launch of trelagliptin and trazodone; external sourcing via universities, research institutes, innovative-drug companies and industry funds.
-
Quality/cost: GMP compliance, batch release, supply stability; production planned on actual orders to cut inefficient capacity and impairments.
-
Market: "terminal-actual-sales-oriented" approach prioritising market order, collection quality and channel inventory; omni-channel (hospitals, distributors, pharmacy chains, e-commerce); orderly international registration and customer sampling.
-
Digital/AI: unified data definitions, online processes, operational dashboards and intelligent analytics across finance, sales, production, quality, supply chain, R&D and HR.
-
Talent: precise recruitment for key positions, cadre evaluation, professional promotion tracks, performance and diversified incentives.
Initiatives announced in the last 24 months
| Date | Initiative | Detail / target | Source |
|---|---|---|---|
| 2024–2025 | R&D organisational consolidation | Integration of all subsidiaries' R&D teams under the Suzhou institute; ~60% of pipeline self-developed | FY24 AR-Ann |
| 2,024 | Retail and e-commerce channel build-out | Deeper pharmacy-chain partnerships; pharmaceutical e-commerce model launched | FY24 AR-Ann |
| Jun 2025 | Exit from Nanjing PharmaRays | Simplified R&D structure | FY25 AR summary |
| Aug 2025 | Dawnrays Global Trading Ltd. | New trading entity (international/trading purpose implied) | FY25 AR summary |
| Mar 2026 | US$14m capital injection into Suzhou Dawnrays | Strengthen operating subsidiary | FY25 AR summary |
| Jun 2026 | Cadre management programme | Phase I diagnosis and gap analysis complete | 1H26 IR |
| Jun–Jul 2026 | Biomedical venture fund | Up to RMB100m commitment; access to deals, technology and returns | 1H26 IR |
| 2,026 | Lanzhou phase II | RMB34.6m for new-product equipment and continuous-flow processes | 1H26 IR |
| 2,026 | Shanfeng Road powder-mixing workshop | ~RMB17.8m | 1H26 IR |
| Jul 2026 | Share option grant | 10m options to employees | 1H26 IR |
Medium-term targets and guidance
Management has not published quantitative revenue or margin targets. The only formal financial commitment is the dividend policy (payout of 25–50% of attributable profit, FY25 AR summary; earlier wording was "at least 25%", FY24 AR-Ann). Qualitative commitments: launch new products every year; achieve carbon peak by 2030 and neutrality by 2060.
Products & Services
Pricing models: all products are sold at tender/VBP-determined or negotiated listing prices to distributors and institutions; individual product prices are not disclosed.
Finished drugs — anti-hypertensives ("An" / 安 series)
| Product / brand | Molecule & description | Target | Status / notes | Source |
|---|---|---|---|---|
| Anneizhen (安內真) | Amlodipine besylate tablets (5mg, 2.5mg passed consistency evaluation); flagship of "An" series | Hypertension patients; strong in second/third-tier terminals | Approved Feb 2004; VBP bid winner; management claims leading position among similar products in many cities/provinces' secondary and tertiary terminals | 2004 AR; FY24 AR-Ann |
| Losartan potassium and hydrochlorothiazide tablets (50/12.5mg) | Fixed-dose ARB/diuretic | Hypertension | Passed consistency evaluation | FY24 AR-Ann |
| Telmisartan tablets (40mg, 80mg) | ARB | Hypertension | Passed consistency evaluation | FY24 AR-Ann |
| Telmisartan and amlodipine tablets (80mg/5mg) | Fixed-dose combination, Class 4 chemical drug | Hypertension | Approved 1H2026 | 1H26 IR |
| Benidipine hydrochloride (process patents) | Calcium channel blocker | Hypertension | Invention patents granted 2024; commercial status not disclosed | FY24 AR-Ann |
"An" series sales: RMB424.2m (FY2023), RMB334.3m (FY2024, 31.5% of group sales), RMB115.3m in 1H2026 (-28.1% YoY) (FY24 AR-Ann; 1H26 IR).
Finished drugs — lipid-lowering and metabolic (mainly Fujian Dawnrays)
| Product / brand | Molecule & description | Target | Status / notes | Source |
|---|---|---|---|---|
| Shumaitong (舒邁通) | Atorvastatin calcium tablets | Hyperlipidaemia | VBP bid winner; retail sales growth | FY24 AR-Ann |
| Rosuvastatin calcium tablets | Statin; formulation and process patents granted 2024 | Hyperlipidaemia | Recognised in Fujian's "New and Excellent" product list (Feb 2026) | FY24 AR-Ann; 1H26 IR |
| Yousuheng (優素衡) | Metformin hydrochloride sustained-release tablets (III) | Type 2 diabetes | Won alliance VBP renewal (2024); Fujian "New and Excellent" list (Feb 2026) | FY24 AR-Ann; 1H26 IR |
| Metformin hydrochloride tablets (0.25g) | Biguanide | Type 2 diabetes | Passed consistency evaluation | FY24 AR-Ann |
| Valsartan and amlodipine tablets | ARB/CCB combination; patent granted 2024 | Hypertension | Fujian "New and Excellent" list (Feb 2026) | FY24 AR-Ann; 1H26 IR |
| Trelagliptin succinate tablets (50mg, 100mg) | Once-weekly DPP-4 inhibitor, Class 3 generic; API also approved (Lanzhou) | Type 2 diabetes | Approved 1H2026; launch preparation under way | 1H26 IR |
Antihyperlipidaemic sales: RMB292.3m (FY2023), RMB299.4m (FY2024, 28.2%); Fujian Dawnrays solid-dose sales RMB178.6m in 1H2026 (+0.4%).
Finished drugs — antiviral
| Product / brand | Description | Target | Status | Source |
|---|---|---|---|---|
| Ruifuen (瑞夫恩) | Entecavir dispersible tablets 0.5mg, using a proprietary cyclodextrin inclusion technology | Chronic hepatitis B | Alliance VBP winner; passed consistency evaluation; 2024 entecavir process invention patent | FY24 AR-Ann |
Sales: RMB124.8m (FY2023), RMB141.2m (FY2024, 13.3%), RMB97.6m in 1H2026 (+21.4%).
Finished drugs — anti-allergy
| Product / brand | Description | Status | Source |
|---|---|---|---|
| Xikewei (西可韋) | Cetirizine hydrochloride tablets 10mg | Passed consistency evaluation | FY24 AR-Ann |
| Xikexin (西可新) | Levocetirizine-class antihistamine (levocetirizine dihydrochloride tablets 5mg passed consistency evaluation; brand-molecule mapping per filings not explicitly confirmed) | Passed consistency evaluation | FY24 AR-Ann |
Combined sales RMB38.0m in 1H2026 (+17.5%).
Finished drugs — antibiotics (cephalosporin powder for injection and oral)
| Product / brand | Description | Status | Source |
|---|---|---|---|
| Xianshu (先舒) | Cefoperazone sodium and sulbactam sodium for injection (1:1), 1.0g | Won 8th national VBP batch | FY24 AR-Ann |
| Xianlian (先聯) | Cefoperazone/sulbactam for injection (2:1), 1.5g and 3.0g | Alliance VBP renewal win | FY24 AR-Ann |
| Xianding (先定) | Cefotaxime sodium for injection 1.0g/2.0g | Alliance VBP win | FY24 AR-Ann |
| Other injectables passing consistency evaluation | Ceftriaxone sodium, cefmetazole sodium (0.5g/1.0g), ceftazidime, cefuroxime sodium (0.75g/1.5g), cefminox sodium, cefoxitin sodium, cefazolin sodium, cefoperazone sodium | Approved | FY24 AR-Ann |
| Oral antibiotics | Azithromycin tablets and suspension, clarithromycin tablets, cefprozil tablets, cefixime tablets (0.1g/0.2g) | Passed consistency evaluation | FY24 AR-Ann |
Powder-for-injection sales: RMB76.2m (FY2023), RMB108.8m (FY2024, 10.3%), RMB51.7m in 1H2026 (-44.0%).
Other finished drugs
| Product / brand | Description | Status | Source |
|---|---|---|---|
| Zhen Tongyan (真侗言) | Loxoprofen sodium tablets 60mg (NSAID) | Alliance VBP win (2024) | FY24 AR-Ann |
| Trazodone hydrochloride tablets (50mg, 100mg) | Antidepressant, Fujian Dawnrays | Approved 1H2026 | 1H26 IR |
| Sitafloxacin aerosol, crisaborole | Invention patents granted 2024 (topical/anti-infective and dermatology); commercial status not disclosed | Pipeline/IP | FY24 AR-Ann |
Intermediates and bulk medicines
| Product | Site | Status | Source |
|---|---|---|---|
| Cefoperazone sodium, sulbactam sodium and combination powder (sterile API) | Suzhou Shanfeng Road | Commercial sales since 2024 | FY24 AR-Ann |
| Cephalosporin intermediates | Lanzhou | Commercial sales | FY24 AR-Ann |
| Cephalosporin APIs, system-specific APIs, enzyme-inhibitor raw materials, health-supplement raw materials | Lanzhou (planned product scope) | Phase I in production; phase II (RMB34.6m) for new products and continuous-flow processes | FY24 AR-Ann; 1H26 IR |
| Trelagliptin succinate API | Lanzhou | Approved 1H2026 | 1H26 IR |
I&B external sales: RMB129.4m (FY2023), RMB42.0m (FY2024), RMB37.6m in 1H2026; exports only RMB1.5m in 1H2026 (-85.7%).
Product revenue snapshot — half-year comparison
| Product line | 1H2025 | 1H2026 |
|---|---|---|
| "An" series anti-hypertensives (RMB M) | 160.3 | 115.3 |
| Fujian Dawnrays solid dose (RMB M) | 177.9 | 178.6 |
| Entecavir dispersible tablets (RMB M) | 80.4 | 97.6 |
| Cephalosporin powder for injection (RMB M) | 92.2 | 51.7 |
| Xikewei and Xikexin (RMB M) | 32.3 | 38.0 |
| Intermediates and bulk medicines, external (RMB M) | 40.2 | 37.6 |
1H2026 values from 1H26 IR; 1H2025 values are analyst-derived by back-calculating from the disclosed 1H2026 growth rates (e.g., 97.624 / 1.214), except I&B which is reported.
Product revenue snapshot — full year
| Product line | FY2023 | FY2024 |
|---|---|---|
| "An" series (RMB M) | 424.2 | 334.3 |
| Antihyperlipidaemic products (RMB M) | 292.3 | 299.4 |
| Antiviral entecavir (RMB M) | 124.8 | 141.2 |
| Powder for injection (RMB M) | 76.2 | 108.8 |
| Intermediates and bulk medicines external (RMB M) | 129.4 | 42.0 |
Source: FY24 AR-Ann.
Financial Narrative
Income statement
Sources: FY2021–FY2024 EPS and profit from company results announcements (FY2021: 27 Mar 2022; FY2022: 26 Mar 2023; FY2023: 22 Mar 2024; FY2024: 28 Mar 2025); revenue, EBIT, EBITDA, pre-tax for FY2021–FY2022 and FY2025 from S&P/SA; FY2025 revenue, attributable profit and EPS from FY25 AR summary.
Adjusted ("operating") profit. Management's own normalised attributable profit, excluding the AD Pharmaceuticals disposal gain, the equipment subsidy and the associate's losses, was RMB250.0m (FY2023) and RMB201.7m (FY2024), down 19.3% (FY24 AR-Ann). FY2025 attributable profit of RMB214.0m contains a RMB33.9m intangible-asset impairment and RMB49.2m of inventory write-downs (FY25 AR summary), so underlying profitability was modestly higher than FY2024 on this basis.
Margins (%)
Revenue CAGR FY2021–FY2025: ~1.4% per year (analyst calculation, RMB1,165m → RMB1,230.9m). Over the same period EBIT fell at a ~12% CAGR, illustrating the margin compression from VBP and new-plant costs.
Interim trend: notes and sources
Source: 1H26 IR. 1H2026 profit grew 18.0% despite a 13.4% revenue decline, because selling expenses fell with a higher VBP mix (VBP products need less promotional spend), R&D dropped 38.4% after phased spending in 1H2025, and fair-value gains on financial assets rose to RMB21.1m from RMB4.5m. Inventory write-downs remained heavy at RMB26.5m.
Balance sheet
Sources: FY24 AR-Ann (FY2023–FY2024); 1H26 IR comparatives (FY2025 year-end); S&P/SA (FY2021–FY2022 and aggregated cash/investment line). Net cash per S&P includes trading securities and structured deposits.
30 June 2026 position (1H26 IR): total assets RMB3,987.9m; cash and bank balances RMB1,293.0m; FVTPL current financial assets RMB299.5m (mainly RMB287m principal-protected structured deposits from eight banks); borrowings only RMB4.5m (discounted notes); debt ratio 0.1%; net assets RMB3,432.2m (RMB2.278 per share); unused bank facilities ~RMB1.94bn.
Cash flow: notes and sources
Source: S&P/SA cash flow statement; FY2023–FY2024 OCF confirmed by FY24 AR-Ann (RMB338.4m and RMB220.2m). 1H2026 OCF RMB190.3m (1H2025: RMB202.0m); investing outflow RMB265.2m; financing outflow RMB133.6m (1H26 IR).
Ratios
ROE for FY2023, FY2024 and FY2025 matches company disclosures (11.4%, 17.0%, 6.3%). Other ratios are analyst calculations from the tables above. 1H2026: current ratio 5.38, quick ratio 4.88 (1H26 IR).
Working-capital cycle (company-disclosed days)
Payable days are not disclosed; trade payables are normally settled on 90-day terms (1H26 IR). An approximate cash conversion cycle using 90 payable days would be ~205 days (FY2024) and ~140 days (1H2026, analyst estimate).
Commentary on trends, inflections and drivers
FY2021–FY2022 (peak). Revenue reached ~RMB1.28bn in FY2022 as the 2019–2020 VBP wins (amlodipine, atorvastatin, entecavir and others) drove volume growth; EBIT margins sat near 33% and gross margins near 60%. The I&B segment was already slipping toward losses.
FY2023–FY2024 (VBP squeeze and relocation drag). Revenue fell 9.9% and 7.9% in successive years. The "An" series dropped from RMB424m to RMB334m in FY2024 as alliance procurement moved from single-winner to multi-winner formats and extended into retail, primary-care and private channels. Simultaneously, the Tianling Road plant relocation and Lanzhou start-up forced API customers to re-qualify the Group's products, collapsing external I&B sales by 67.5% in FY2024 and triggering RMB43.9m of inventory write-downs. Reported profit was nevertheless flattered by one-offs: RMB139.8m relocation compensation in FY2023 and RMB286.7m AD Pharmaceuticals gain plus a RMB105.0m pre-tax equipment subsidy in FY2024.
FY2025 (volume rebound, earnings normalisation). Revenue rebounded 16.1% to RMB1,230.9m, driven by cephalosporin injectables and resumed I&B sales, but attributable profit fell 62% to RMB214.0m because the FY2024 one-offs did not recur, R&D rose, and the Group booked RMB33.9m intangible impairment and RMB49.2m inventory write-downs (FY25 AR summary). Free cash flow of RMB269.4m was the strongest in five years as capex fell to RMB86.0m post-construction.
1H2026 (price reset, cost discipline). Revenue fell 13.4% as VBP batch 1–8 continuation pricing (effective 31 Mar 2026) hit powder injections (-44%) and price governance cut "An" series sales (-28%). Profit nevertheless rose 18% via lower selling, admin and R&D expenses plus higher fair-value gains. Quality of earnings is therefore lower than the headline suggests: management itself flags continuing impairment and gross-profit pressure on intermediates, APIs and injectables (1H26 IR).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Ownership | Role | Source |
|---|---|---|---|---|
Dawnrays Pharmaceutical (Holdings) Ltd. | Cayman Islands | Listed parent | Holding | 1H26 IR |
Dawnrays International Ltd. (formerly Dawnrays International Co. Ltd.) | BVI | 100% | Intermediate holding; funds PRC subsidiaries (US$10m to Suzhou in 2024; US$14m in Mar 2026) | FY24 AR-Ann; FY25 AR summary |
Dawnrays International Company Limited | Hong Kong | 100% | Holding | Interim Report 2025 group chart |
Dawnrays Pharma (Hong Kong) Ltd. | Hong Kong | 100% | Holding/trading | Interim Report 2025 group chart |
Dawnrays Biotechnology Capital (Asia) Ltd. | Hong Kong | 100% | Investment vehicle (formerly held AD Pharmaceuticals stake) | FY24 AR-Ann |
Dawnrays Global Trading Ltd. | — | 100% (presumed) | Trading; established Aug 2025 | FY25 AR summary |
Top Field Limited | — | 100% | Holding company of Fujian Dawnrays; source of RMB241.2m goodwill | 1H26 IR |
Suzhou Dawnrays Pharmaceutical Co., Ltd. | PRC (Jiangsu) | 100% | Main operating company; R&D institute; Shanfeng Road API/formulation plant | 1H26 IR |
Fujian Dawnrays Pharmaceutical Co., Ltd. | PRC (Putian, Fujian) | 100% | Solid-dose chronic-disease generics (statins, metformin, valsartan/amlodipine, trazodone) | 1H26 IR |
Lanzhou Dawnrays Pharmaceutical Co., Ltd. | PRC (Gansu) | 100% | Intermediates and API base (250 mu site) | FY24 AR-Ann |
Suzhou Dawnrays Pharmaceutical Trading Co., Ltd. | PRC | 100% | Pharma trading agency (not operational as of FY2024) | FY24 AR-Ann |
Shanghai Jianxin Dawnrays Biomedical Industry Venture Capital Partnership (LP) | PRC | LP interest, up to RMB100m commitment (50%) | Venture fund; registered 28 Jul 2026 | 1H26 IR |
Nanjing PharmaRays Science and Technology Co., Ltd. | PRC | Was 65%; disposed Jun 2025 | Former R&D subsidiary | FY25 AR summary |
“—” = not publicly disclosed.
Segment Overview
| Segment | Contents | Products | Measurement basis |
|---|---|---|---|
Finished drugs | Manufacture and sale of antibiotic and non-antibiotic finished drugs | "An" series, Fujian Dawnrays solid dose, entecavir, antihistamines, cephalosporin powder for injection, oral cephalosporins and other antibiotics | Segment result = adjusted profit before tax, excluding interest income, non-lease finance costs, government grants, dividend income, FV gains, head-office costs |
Intermediates and bulk medicines | Manufacture and sale of intermediates and APIs (external + intersegment) | Cefoperazone sodium, sulbactam sodium and combination powder, other cephalosporin APIs and intermediates, specialty APIs (e.g., trelagliptin) | Same; intersegment sales at prevailing market prices |
Revenue by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Finished drugs revenue (CNY Mn) | 1,010 | 1,140 | 1,021.7 | 1,018.3 | 1,160 |
Intermediates and bulk medicines total revenue incl. intersegment (CNY Mn) | 216 | 205 | 210.1 | 151.4 | 177 |
Intersegment elimination (CNY Mn) | -61.4 | -64.6 | -80.6 | -109.3 | -107 |
Intermediates and bulk medicines external revenue (CNY Mn) | 154.6 | 140.4 | 129.4 | 42.0 | 70 |
Group revenue (CNY Mn) | 1,165 | 1,278 | 1,151.1 | 1,060.3 | 1,230.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Finished drugs segment result (CNY Mn) | 546 | 609 | 487.3 | 425.2 | 496 |
Intermediates and bulk medicines segment result (CNY Mn) | -2.3 | -17.8 | -32.7 | -61.0 | -69.5 |
Finished drugs segment margin (%) | 54.1 | 53.4 | 47.7 | 41.8 | 42.8 |
Finished drugs share of group revenue (%) | 86.7 | 89.2 | 88.8 | 96.0 | 94.3 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | 1H2025 | 1H2026 |
|---|---|---|
Finished drugs revenue (CNY Mn) | 590.2 | 508.2 |
I&B external revenue (CNY Mn) | 40.2 | 37.6 |
I&B intersegment revenue (CNY Mn) | 45.5 | 39.6 |
Finished drugs segment result (CNY Mn) | 250.9 | 241.2 |
I&B segment result (CNY Mn) | -25.2 | -39.7 |
Finished drugs segment margin (%) | 42.5 | 47.5 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 1,165 | 1,278 | 1,151.1 | 1,060.3 | 1,230.9 |
Revenue growth (%) | 13.8 | 9.7 | -9.9 | -7.9 | 16.1 |
Gross profit, S&P standardised (CNY Mn) | 675.4 | 766.7 | 628.5 | 532.1 | 557.4 |
Operating income / EBIT, S&P (CNY Mn) | 380.8 | 419.1 | 276.0 | 202.1 | 227.4 |
EBITDA, S&P (CNY Mn) | 433.9 | 480.1 | 354.4 | 302.8 | 343.7 |
Pre-tax income (CNY Mn) | 439.3 | 438.4 | 414.1 | 636.9 | 249.6 |
Income tax (CNY Mn) | 85.2 | 82.6 | 91.4 | 74.2 | 38.5 |
Profit for the year (CNY Mn) | 354.2 | 355.9 | 322.7 | 562.8 | 211.1 |
Profit attributable to owners (CNY Mn) | 358.2 | 358.1 | 326.0 | 564.9 | 214.0 |
EPS basic (MYR Bn) | 0.2392 | 0.2389 | 0.2174 | 0.3754 | 0.14 |
EPS diluted (MYR Bn) | 0.2375 | 0.2383 | 0.2170 | 0.3752 | 0.14 |
R&D expense (CNY Mn) | 67.0 | 79.5 | 90.8 | 70.8 | 83.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin, S&P basis (%) | 58.0 | 60.0 | 54.6 | 50.2 | 45.3 |
Gross margin, company basis (%) | 58.0 | 60.0 | 55.7 | 54.5 | 45.3 |
Operating (EBIT) margin (%) | 32.7 | 32.8 | 24.0 | 19.1 | 18.5 |
EBITDA margin (%) | 37.2 | 37.6 | 30.8 | 28.6 | 27.9 |
Net margin, attributable (%) | 30.7 | 28.0 | 28.3 | 53.3 | 17.4 |
Effective tax rate (%) | 19.4 | 18.8 | 22.1 | 11.6 | 15.4 |
Income Statement and Per-Share Data
| Metric | 1H2025 | 1H2026 |
|---|---|---|
Revenue (CNY Mn) | 630.4 | 545.8 |
Gross profit, company (CNY Mn) | 314.0 | 282.8 |
Selling and distribution expenses (CNY Mn) | 56.8 | 39.4 |
Administrative expenses (CNY Mn) | 67.5 | 62.1 |
R&D costs (CNY Mn) | 56.8 | 35.0 |
Other expenses (CNY Mn) | 33.1 | 30.5 |
Other income and gains (CNY Mn) | 30.9 | 43.0 |
Profit before tax (CNY Mn) | 130.3 | 158.2 |
Profit attributable (CNY Mn) | 104.6 | 123.3 |
EPS basic (MYR Bn) | 0.06961 | 0.08200 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 3,340 | 3,673 | 3,622.7 | 4,009.3 | 4,009.4 |
Cash and bank balances (CNY Mn) | 577.7 | 811.7 | 905.8 | 1,158.3 | 1,166.4 |
Cash plus short-term and trading investments, S&P (CNY Mn) | 830.2 | 1,082 | 1,174 | 1,608 | 1,805 |
Short-term borrowings (CNY Mn) | 21.0 | 6.4 | 120.1 | 29.9 | 77.5 |
Long-term debt incl. leases (CNY Mn) | 2.5 | 2.0 | 0.5 | 4.9 | 0 |
Total debt (CNY Mn) | 23.5 | 8.4 | 120.5 | 34.7 | 77.5 |
Net cash (CNY Mn) | 806.7 | 1,073 | 1,053 | 1,573 | 1,727 |
Total equity (CNY Mn) | 2,398 | 2,650 | 2,859.2 | 3,326.7 | 3,385.0 |
Goodwill (CNY Mn) | 241.2 | 241.2 | 241.2 | 241.2 | 241.2 |
Inventories (CNY Mn) | 203.5 | 241.8 | 211.1 | 308.2 | 215.4 |
Working capital (CNY Mn) | 813.9 | 811.9 | 1,051.3 | 1,647.6 | 1,799.7 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 393.1 | 434.3 | 338.4 | 220.2 | 355.4 |
Capital expenditure (CNY Mn) | 313.1 | 204.4 | 199.6 | 126.0 | 86.0 |
Free cash flow (CNY Mn) | 80.1 | 229.9 | 138.9 | 94.2 | 269.4 |
Purchase of intangibles (CNY Mn) | 90.0 | 21.3 | 12.5 | 49.6 | 33.4 |
Dividends paid (CNY Mn) | 143.9 | 99.5 | 117.1 | 111.2 | 132.9 |
Share buybacks (CNY Mn) | 15.5 | 0 | 0 | 0 | 0 |
Depreciation and amortisation (CNY Mn) | 56.4 | 64.4 | 81.9 | 104.5 | 119.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable profit / year-end attributable equity (%) | 15.0 | 13.6 | 11.4 | 17.0 | 6.3 |
ROA, attributable profit / total assets (%) | 10.7 | 9.7 | 9.0 | 14.1 | 5.3 |
ROIC, NOPAT / (equity + debt - cash and investments) (%) | 19.3 | 21.6 | 11.9 | 10.2 | 11.6 |
Current ratio (x) | 2.17 | 1.87 | 2.57 | 3.97 | 4.64 |
Debt to equity (%) | 1.0 | 0.3 | 4.2 | 1.0 | 2.3 |
Net debt to EBITDA (x) | -1.86 | -2.24 | -2.97 | -5.19 | -5.02 |
Interest coverage, EBIT / interest expense (x) | 595 | 1,133 | 279 | 56 | 455 |
Asset turnover, revenue / total assets (x) | 0.35 | 0.35 | 0.32 | 0.26 | 0.31 |
Working Capital (Days)
| Metric | FY2024 | 1H2026 |
|---|---|---|
Trade receivable days | 48 | 44 |
Trade and notes receivable days | 101 | 85 |
Inventory days | 194 | 145 |
Revenue by Region and Revenue by Region (%)
| Region | FY2023 | FY2024 |
|---|---|---|
Mainland China (CNY Mn) | 1,134.4 | 1,049.0 |
Other countries (CNY Mn) | 16.7 | 11.3 |
Mainland China share (%) | 98.5 | 98.9 |
Revenue by Region and Revenue by Region (%) (1H2025–1H2026)
| Region | 1H2025 | 1H2026 |
|---|---|---|
Mainland China (CNY Mn) | 619.8 | 544.3 |
Other countries (CNY Mn) | 10.7 | 1.5 |
Mainland China share (%) | 98.3 | 99.7 |
Revenue by Region
| Segment and region | FY2023 | FY2024 |
|---|---|---|
Finished drugs — Mainland China (CNY Mn) | 1,016.5 | 1,018.5 |
Finished drugs — other countries (CNY Mn) | 5.3 | 0 |
I&B — Mainland China (CNY Mn) | 118.0 | 30.5 |
I&B — other countries (CNY Mn) | 11.5 | 11.3 |
Revenue by Region (1H2025–1H2026)
| Segment and region | 1H2025 | 1H2026 |
|---|---|---|
Finished drugs — Mainland China (CNY Mn) | 590.2 | 508.2 |
I&B — Mainland China (CNY Mn) | 29.6 | 36.1 |
I&B — other countries (CNY Mn) | 10.7 | 1.5 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price | HK$0.96 (8 Oct 2026) | S&P/SA |
52-week change | -19.3% (as of 15 Sep 2026) | S&P/SA |
50-day / 200-day moving average | HK$1.00 / HK$1.11 (15 Sep 2026) | S&P/SA |
Year-to-date (to 31 Jul 2026) | ~-15% (HK$1.04 close) | Zonebourse |
Beta (5Y) | 0.23 | S&P/SA |
Average daily volume (20 days) | ~156,000 shares (very illiquid) | S&P/SA |
Historical reference | Stock traded at ~HK$7.7 in Oct 2014 (pre-2018 2-for-1 split; ~HK$3.9 split-adjusted) per HKEX disclosure forms | HKEX DI |
Valuation Multiples
| Multiple | Dawnrays | Comment |
|---|---|---|
P/E (TTM) | 5.6x | S&P/SA |
P/E (FY2025) | 7.8x | MarketScreener |
P/B | 0.37x | S&P/SA |
P/TBV | 0.44x | S&P/SA |
EV/Sales | Negative (~-0.06x on FY2025 basis) | MarketScreener; EV negative |
EV/EBITDA | Negative / not meaningful | Net cash exceeds market cap |
Dividend yield | ~6.3% trailing | S&P/SA |
Dividends & Capital Returns (HKD) and Returns & Leverage Ratios (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Interim dividend (HKD) | 0.015 | 0.015 | 0.015 |
Final dividend (HKD) | 0.065 | 0.048 | 0.048 |
Special dividend (HKD) | 0 | 0.032 | 0 |
Total dividend (HKD) | 0.080 | 0.095 | 0.063 |
Payout ratio (%) | 34.0 | 23.5 | 39.3 |
Analyst Conclusions
Management guidance
No numerical guidance. Management expects continued price compression for homogeneous generics, emphasises financial prudence, cost and supply competitiveness, launch of newly approved products (trelagliptin, trazodone), external pipeline sourcing, order-based production to reduce impairments, and orderly international registration (1H26 IR).
Consensus
None available.
Bull case
-
Deep value with downside protection: at ~HK$1.45bn market cap the shares trade below net cash and liquid investments (~RMB1.6bn, ~HK$1.75bn) and at 0.37x book; even a modest earnings base supports a ~6% yield.
-
Operating leverage from idle capacity: the I&B segment lost ~RMB70m in FY2025; converting Shanfeng Road and Lanzhou to break-even through API filings, trelagliptin API and exports would lift group pre-tax profit by roughly a quarter versus FY2025.
-
Pipeline and channel replenishment: six approvals in 1H2026, 15 pending, and a funded M&A/venture channel could offset "An" series erosion, while entecavir (+21%) and antihistamines (+17.5%) are still growing.
Bear case
-
Structural price deflation: VBP continuation and price governance drove a 13.4% revenue decline in 1H2026, and the 12th batch plus price-formation reforms imply further cuts.
-
Value trap dynamics: controlled ownership, ~3% institutional ownership and thin liquidity mean the cash discount may never close; cash is being deployed into low-return plants and funds rather than buybacks.
-
Earnings quality and impairment risk: recurring inventory write-downs (RMB26–49m per period), FV-gain-dependent profit growth, and RMB241m Fujian goodwill against flat Fujian sales.
Catalysts and monitorables (next 12 months)
-
12th national VBP batch results and Dawnrays' winning products (expected late 2026).
-
Launch progress of trelagliptin and trazodone; CDE decisions on 15 pending applications.
-
I&B segment loss trajectory and Shanfeng Road utilisation in the FY2026 annual results (expected March 2027).
-
Collection of the remaining RMB175.6m relocation compensation.
-
HNTE tax-status renewal for Suzhou Dawnrays (from 2026).
-
Deployment of the RMB100m venture fund and any acquisition.
-
Any capital-return action (buyback or special dividend) given net cash.
-
Interim Report 2026 publication and FY2026 dividend decision.
Analyst verdict
Dawnrays is a financially conservative, cash-rich Chinese generic drug company whose core economics have been structurally reset by volume-based procurement. The finished-drug franchise still earns segment margins in the 40s and throws off strong cash (FY2025 free cash flow of RMB269m), and the balance sheet is exceptional for its size: roughly RMB1.6bn of cash and principal-protected deposits, negligible debt and RMB3.4bn of net assets. Against that, revenue has gone nowhere for five years (≈1.4% CAGR FY2021–FY2025), EBIT has fallen from RMB419m to RMB227m, and headline profits since 2023 have been propped up by one-offs (relocation compensation, the AD Pharmaceuticals sale, an equipment subsidy) and, in 1H2026, by fair-value gains and lower R&D spend.
The investment debate therefore centres on two questions. First, can management turn the ~RMB700m of upstream assets at Suzhou Shanfeng Road and Lanzhou from a ~RMB70m annual drag into a contributor? Evidence so far — falling external API sales, near-zero exports and repeated inventory write-downs — is not encouraging, although domestic API sales grew in 1H2026 and new APIs such as trelagliptin are now approved. Second, will the controlling shareholders allow the balance sheet to work harder for minority investors? The 25–50% payout policy and 6%+ yield are positives, but there have been no buybacks since 2021 even with the stock below net cash.
On balance, the shares look statistically cheap (≈5.6x trailing earnings, 0.37x book, negative enterprise value), and the downside is cushioned by cash. However, the absence of a visible growth engine, continuing VBP price resets in 2026, illiquidity and governance concentration argue that the discount is likely to persist without a catalyst. The stock is best viewed as a high-yield, low-beta value holding whose re-rating depends on demonstrable I&B break-even, successful new-product launches through the 12th VBP batch, or a decisive capital-return step.
Data gaps flagged (not publicly disclosed in materials reviewed): FY2025 product-level and geographic revenue; FY2025 company-basis gross profit; director and executive compensation; director ages and education; full institutional holder list; total patent portfolio; ESG emissions metrics and third-party ratings; 3- and 5-year share-price returns; subject of the 29 May 2026 Fujian Dawnrays announcement; Fujian Dawnrays acquisition date and price.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Committees | Tenure / notes | Source |
|---|---|---|---|---|
Ms. LI Kei Ling (李其玲) | Executive Director, Chairman | Chair of Nomination; member of Remuneration | — | 1H26 IR; AR2024 corporate information |
Mr. HUNG Yung Lai (熊融禮) | Executive Director | — | — | 1H26 IR |
Mr. LEUNG Hong Man (梁康民) | Non-executive Director | — | Historical substantial holder (~6% in 2014 per HKEX disclosure of interests); absent from 22 May 2026 AGM | 1H26 IR; HKEX DI forms |
Mr. HU Shuo | Non-executive Director | — | Appointed 1 Aug 2025 | MarketScreener (company announcement 31 Jul 2025) |
Mr. LO Tung Sing Tony (勞同聲) | Independent Non-executive Director | Chair of Audit; member of Remuneration and Nomination | Absent from 2024 AGM | 1H26 IR; FY24 AR-Ann |
Mr. EDE, Ronald Hao Xi | Independent Non-executive Director | Chair of Remuneration; member of Audit and Nomination | Absent from 2024 AGM | AR2024; FY24 AR-Ann |
Ms. LAM Ming Yee Joan (林明儀) | Independent Non-executive Director | Member of Audit, Remuneration and Nomination | — | AR2024; 1H26 IR |
Executive Leadership Team
| Name | Title | Tenure | Source |
|---|---|---|---|
Ms. 于麗偉 (Yu Liwei, pinyin rendering) | Chief Executive Officer (總裁) | Appointed 13 Sep 2024; holds share options under the 2023 scheme (FY25 AR summary notes options are held mainly by the CEO and employees) | AR2024 corporate information |
Mr. 吳偉賢 (Wu Weixian, pinyin rendering) | Former CEO | Resigned 11 Sep 2024 | AR2024 corporate information |
Ms. Pang Kit Ling | Company Secretary | — | Board notice 14 Mar 2025 |
Dean, Suzhou Dawnrays Advanced Technology Research Institute (name not disclosed) | Head of Group R&D | Hired late 2024 | FY24 AR-Ann |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
11/13 Sep 2024 | CEO transition from 吳偉賢 to 于麗偉 | Coincided with plant ramp-up difficulties and R&D reorganisation |
Late 2024 | New Ph.D. dean of R&D institute | To consolidate R&D teams across Fujian, Suzhou, Lanzhou and Nanjing |
1 Aug 2025 | Hu Shuo appointed NED | Board expanded from 6 to 7 |
Jun 2026 | Cadre management programme launched (phase I diagnostic complete) | Management-capability upgrade |
3 Jul 2026 | 10,000,000 share options granted under 2023 scheme | Employee incentive |
Major Shareholders
| Holder | Approx. stake | Notes / source |
|---|---|---|
Fortune United Group Limited (BVI) | ~39% | Ultimate holding company per 1H26 IR; stake per Simply Wall St (date of data not specified) |
Ms. Li Kei Ling | ~7.0% | Simply Wall St (date not specified) |
Toyo International Investment Limited | ~6.6% | Simply Wall St (date not specified) |
Insiders (aggregate) | 12.69% | S&P/SA, Sep 2026 |
Institutions (aggregate) | 3.19% | S&P/SA, Sep 2026 |
Free float | ~490m shares (~33%) | S&P/SA; public float ≥25% confirmed in FY25 AR summary |
Competitive Landscape
Competitors by Segment
| Segment / product area | Competitors | Relative positioning |
|---|---|---|
Amlodipine and other anti-hypertensives | Viatris (Pfizer legacy Norvasc), Zhejiang Huahai Pharmaceutical (sartans), CSPC Pharmaceutical Group, multiple VBP winners | Dawnrays strong in second/third-tier terminals (company claim), but faces multi-winner VBP dilution |
Statins (atorvastatin, rosuvastatin) | Viatris (Lipitor), AstraZeneca (Crestor), Beijing Jialin (Lepu Medical), Qilu Pharmaceutical, Zhejiang Hisun | Fujian Dawnrays claims leading position in Chinese sales (company claim) |
Entecavir | Bristol Myers Squibb (Baraclude), Chia Tai Tianqing (Sino Biopharmaceutical), Qilu, Jiangxi Qingfeng | Differentiated dispersible formulation; company claims a leading position |
Cephalosporin injectables | Qilu Antibiotics, Reyoung Pharmaceutical, North China Pharmaceutical, Shandong Lukang, Hainan Poly Pharm, Joincare | Mid-sized participant; VBP-driven volatility |
Cephalosporin intermediates/APIs | The United Laboratories (3933.HK, broader antibiotic API), Qilu Antibiotics, Shandong Lukang, ACS Dobfar (Italy), Indian API makers | Sub-scale; loss-making since capacity relocation |
Antihistamines | UCB/Kenvue (Zyrtec), domestic generics (Suzhou and Jiangsu peers) | Niche |
HK-listed generic peers (investor comparables) | SSY Group (2005.HK), The United Laboratories (3933.HK), China Medical System (0867.HK), Lee's Pharmaceutical (0950.HK) | Dawnrays is among the smallest by revenue |
Peer Comparison FY2025
| Metric | Dawnrays (2348.HK) | The United Laboratories (3933.HK) | SSY Group (2005.HK) |
|---|---|---|---|
Revenue (local currency M) | RMB 1230.9 | RMB 13210.6 | HK$ 4165 |
Revenue growth YoY (%) | 16.1 | -4.0 | -27.8 |
Gross margin (%) | 45.3 | 41.7 | 41.6 |
Net margin, attributable (%) | 17.4 | 15.8 | 11.3 |
R&D intensity (%) | 6.8 | 7.0 | 5.9 |
Net cash / (debt) position | Net cash ~RMB1.7bn | Not computed | Net debt (borrowings HK$4,011m vs cash HK$1,691m) |
Recent Developments
Headcount fell from 1,183 (end-2024) to 1,074 (Jun 2026), partly due to the Nanjing PharmaRays disposal.



